Tiziana Life Sciences rises as nasal MS drug shows promise in early study

Tiziana Life Sciences

25/02/2026 12:33

** Shares of biotech firm Tiziana Life Sciences TLSA.O rise 3% to $1.36 premarket

** Co says its experimental nasal drug for multiple sclerosis showed early signs of reducing brain inflammation in a small study

** Multiple sclerosis is an autoimmune nerve disorder where the immune system attacks the protective coating around nerves, disrupting signals between the brain and body

**  Co says all 10 patients in the early study had stable or improved disease with no serious side effects

**  Study showed reduced brain inflammation on scans and spinal fluid changes linked to lower inflammation and improved nerve protection, per co

**  Co is testing the drug in a larger mid-stage trial with results expected in 1H 2026 - TLSA

** Shares up ~114% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))